BPC-157 + TB-500 Peptide Stack — Research Compound Overview

BPC-157 (pentadecapeptide, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, CAS 137525-51-0, MW 1419.53 Da) is a synthetic 15-amino acid sequence derived from a 62-amino acid human gastric juice protective protein (BPC). In pre-clinical research (primarily Sikiric's group at Zagreb University and collaborating institutions, with hundreds of published papers), BPC-157 has been investigated in models spanning: gastrointestinal mucosal protection (cytoprotection, ulcer healing, IBD models), musculoskeletal repair (tendon, muscle, ligament, bone injury models), neurological models (traumatic brain injury, spinal cord, peripheral nerve crush), cardiovascular models (fistula formation, heart damage), and systemic organ protection. BPC-157 is proposed to act through nitric oxide (NO) synthesis modulation, VEGF upregulation (promoting angiogenesis at injury sites), FAK and paxillin signaling (cell migration and wound healing), and growth hormone receptor regulation. It is notably stable in gastric acid, enabling oral administration in rodent models without degradation — an unusual property for a peptide.

TB-500 (Tβ4 fragment 17-23, Ala-Cys-Ser-Asp-Lys-Pro-Asp (LKKTETQ more precisely; the active fragment often described as 'Tβ4 central fragment'), CAS 77591-33-4) is the central actin-binding domain fragment of Thymosin Beta-4 (Tβ4, 43 aa). The full-length Tβ4 is the most abundant G-actin-sequestering protein in vertebrate cells, preventing actin polymerization under basal conditions. TB-500 (the fragment) retains the actin-binding LKKTET hexapeptide core and the reported tissue-repair properties of Tβ4, including: promotion of angiogenesis, stem cell recruitment, anti-inflammatory modulation, and matrix metalloproteinase (MMP) regulation. Research on TB-500 spans cardiac regeneration (Tβ4 promotes cardiomyocyte migration in infarct models), skin wound healing, neurological models, corneal healing, and muscle repair. TB-500's small size vs full-length Tβ4 makes it practically accessible as a synthetic research compound.

Research rationale for the BPC-157 + TB-500 combination derives from complementary rather than redundant mechanisms. BPC-157 primarily targets NO signaling, GHR axis modulation, and cytoprotection across GI/systemic tissues. TB-500 primarily targets G-actin sequestration, angiogenesis (via VEGF and fibronectin upregulation), stem cell recruitment, and cytoskeletal remodeling. The two compounds are proposed to act synergistically in injury models: BPC-157 initiating rapid cytoprotection and vasoprotective signaling, TB-500 amplifying the angiogenic and cell-migration responses required for tissue repair completion. Published pre-clinical work examining the combination (tendon, muscle, and bone models) reports enhanced healing timelines vs either compound alone, though these studies are primarily from Sikiric's group. Independent replication data for the combination specifically is limited; the individual compound literatures are substantially larger. DMV Research supplies the BPC-157 + TB-500 blend as a lyophilized co-formulation with per-batch Certificate of Analysis confirming identity of both peptides by mass spectrometry and purity ≥99% by HPLC.